K******S
发帖数: 10109 | 1 可以注意一下NCI CPTC FUND的5个SITES。1年大概5个MILLION的DIRECT COST。这个机
会太诱人了，连MATTHIAS MANN都像分一杯羹.想找这方面工作的XDJM就更得注意了，这
些人可能已经开始招兵买马了。 | p*****1
发帖数: 330 | 2 这个领域的前景如何？
【在 K******S 的大作中提到】
: 可以注意一下NCI CPTC FUND的5个SITES。1年大概5个MILLION的DIRECT COST。这个机
: 会太诱人了，连MATTHIAS MANN都像分一杯羹.想找这方面工作的XDJM就更得注意了，这
: 些人可能已经开始招兵买马了。
| d***y
发帖数: 8107 | 3
我竟然在MATTHIAS MANN实验室的people那一项里面，发现一个名字和我一模一样的，
sigh…………
【在 K******S 的大作中提到】
: 可以注意一下NCI CPTC FUND的5个SITES。1年大概5个MILLION的DIRECT COST。这个机
: 会太诱人了，连MATTHIAS MANN都像分一杯羹.想找这方面工作的XDJM就更得注意了，这
: 些人可能已经开始招兵买马了。
| j*****d
发帖数: 787 | 4 Protein modification
很好的
将军的这个方向也没什么大错
★ 发自iPhone App: ChineseWeb - 中文网站浏览器
【在 p*****1 的大作中提到】
: 这个领域的前景如何？
| w****s
发帖数: 235 | | s******y
发帖数: 28562 | 6 Protein modification 里面，除了John Yates 之外做得比较好的组有哪几个？
【在 j*****d 的大作中提到】
: Protein modification
: 很好的
: 将军的这个方向也没什么大错
:
: ★ 发自iPhone App: ChineseWeb - 中文网站浏览器
| K******S
发帖数: 10109 | 7 Broad Institute (Steven A. Carr, Ph.D.); Fred Hutchinson Cancer Research
Center (Amanda G. Paulovich, M.D., Ph.D.)
Johns Hopkins University (Daniel W. Chan, Ph.D.; Zhen Zhang, Ph.D.; Hui
Zhang, Ph.D.)
Pacific Northwest National Laboratory (Richard D. Smith, Ph.D.; Karin D.
Rodland, Ph.D.)
Vanderbilt University (Daniel C. Liebler, Ph.D.)
Washington University (Matthew J. C. Ellis, M.B., Ph.D.; R. Reid Townsend, M
.D., Ph.D. ); University of North Carolina, Chapel Hill (Xian Chen, Ph.D.);
Boise State University (Morgan C. Giddings, Ph.D.)
【在 w****s 的大作中提到】
: KingofMS: 都fund 谁了？
| I*****y
发帖数: 6402 | 8 Princeton的那个 Benjamin Garcia没拿到钱吗？呵呵
M
;
【在 K******S 的大作中提到】
: Broad Institute (Steven A. Carr, Ph.D.); Fred Hutchinson Cancer Research
: Center (Amanda G. Paulovich, M.D., Ph.D.)
: Johns Hopkins University (Daniel W. Chan, Ph.D.; Zhen Zhang, Ph.D.; Hui
: Zhang, Ph.D.)
:
: Pacific Northwest National Laboratory (Richard D. Smith, Ph.D.; Karin D.
: Rodland, Ph.D.)
:
: Vanderbilt University (Daniel C. Liebler, Ph.D.)
:
| K******S
发帖数: 10109 | 9 not on the list, so definitely no.
This time the competition is fierce. Even M. Mann teamed up with someone in
new york but they didn't get funded.
【在 I*****y 的大作中提到】
: Princeton的那个 Benjamin Garcia没拿到钱吗？呵呵
:
: M
: ;
| w****s
发帖数: 235 | 10
Thank you.
【在 K******S 的大作中提到】
: Broad Institute (Steven A. Carr, Ph.D.); Fred Hutchinson Cancer Research
: Center (Amanda G. Paulovich, M.D., Ph.D.)
: Johns Hopkins University (Daniel W. Chan, Ph.D.; Zhen Zhang, Ph.D.; Hui
: Zhang, Ph.D.)
:
: Pacific Northwest National Laboratory (Richard D. Smith, Ph.D.; Karin D.
: Rodland, Ph.D.)
:
: Vanderbilt University (Daniel C. Liebler, Ph.D.)
:
| w****s
发帖数: 235 | 11
in
what has been worked out for "clinical proteomics"? biomarker discovery was
a joke long time ago ,now the instrument gets more sensitive but dynamic
range is still a major challenge..I heard Ruedi was working on the topic he
knows well how to sell ideas but I did not hear anything exciting.any solid
idea that one could do with clinical proteomics?
【在 K******S 的大作中提到】
: not on the list, so definitely no.
: This time the competition is fierce. Even M. Mann teamed up with someone in
: new york but they didn't get funded.
| w****s
发帖数: 235 | 12
john yates???
【在 s******y 的大作中提到】
: Protein modification 里面，除了John Yates 之外做得比较好的组有哪几个？
| K******S
发帖数: 10109 | 13 there is actually a little bit of history about NCI's CPTC. This time is
actually the 2nd phase. PhaseI also funded 5 sites, the goal was trying to
standardize the filed. But with so much money, most ppl from PhaseI just
took the money and did whatever they wanted. So PhaseI is not very
successful. (that's why only 2 sites from PhaseI got renewed to continue to
Phase II). Phase II is to focus on real clinical samples (several types of
tumor tissue samples), aka the real biomarker discovery phase.
overall, the whole field is shifting toward MRM.
was
he
solid
【在 w****s 的大作中提到】
:
: john yates???
| B*M
发帖数: 1418 | 14 原来你是做proteomics的?
to
【在 K******S 的大作中提到】
: there is actually a little bit of history about NCI's CPTC. This time is
: actually the 2nd phase. PhaseI also funded 5 sites, the goal was trying to
: standardize the filed. But with so much money, most ppl from PhaseI just
: took the money and did whatever they wanted. So PhaseI is not very
: successful. (that's why only 2 sites from PhaseI got renewed to continue to
: Phase II). Phase II is to focus on real clinical samples (several types of
: tumor tissue samples), aka the real biomarker discovery phase.
: overall, the whole field is shifting toward MRM.
:
: was
|
|
